Bone is a major site of haematogenous tumour cell spread in renal cell carcinoma (RCC),
and most patients with RCC will develop painful and functionally disabling bone metastases …

About one-third of patients with advanced renal cell carcinoma (RCC) have bone metastasis
that are often osteolytic and cause substantial morbidity, such as pain, pathologic fracture …

Despite the rapid elaboration of multiple, novel systemic agents introduced for metastatic
renal cell carcinoma (mRCC) in recent years, a durable complete response remains elusive …

Recently, the prognosis of metastatic renal cell carcinoma (mRCC) has improved owing to
the development of immunotherapy using immune checkpoint inhibitors (ICIs). However …

Background Bone metastases (BM) in renal cell carcinoma (RCC) patients are associated
with poor outcomes. There are limited published data on outcomes in these patients with …

Study Design: Systematic review. Objectives: The objective of this systematic review was to
answer 2 key questions:(1) What is the clinical presentation and probability of symptomatic …

Simple Summary Patients with metastatic spine disease face significant challenges and
limitations with current therapy options. The aim of this study is to explore the existing …

Kidney cancer is the 9th most common cancer in men and the 14th most common in women
worldwide. Renal cell carcinoma (RCC) constitutes 90% of all malignancies of the kidney …

Background The outcomes for patients with metastatic renal cell carcinoma (RCC) to the
spine who underwent stereotactic body radiotherapy (SBRT) through a multidisciplinary …

Enlarged bone metastasis from renal cell carcinoma (RCC) can cause skeletal‑related
events, and thus treatment to inhibit the growth of bone metastases is often required …